Sofinnova Partners | Activity | F4

Team Portfolio Raise Champions Essays

F4/Sofinnova Partners/Activity

Sofinnova Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

3 milestones· SEP 2026Show all

Milestone

Portfolio company Julier Medical appointed medtech industry veteran Will Martin as President and CEO.

Julier Medical

Julier Medical Sofinnova Partners

sofinnovapartners.comSEP 24, 2026

SEP 24, 2026

Milestone

Portfolio company Sensorion reported 2026 half-year results and provided a corporate update.

Sensorion

Sensorion Sofinnova Partners

sofinnovapartners.comSEP 23, 2026

SEP 23, 2026

Milestone

Portfolio company ProQR appointed Chris Hart as Chief Data and AI Officer and Thomas Wolf to its Board as Strategic AI Advisor.

ProQR Therapeutics

ProQR Therapeutics Sofinnova Partners

sofinnovapartners.comSEP 23, 2026

SEP 23, 2026

Investment

Portfolio company EnginZyme raised a SEK 75 million equity round to bolster its commercial strategy.

EnginZyme

EnginZyme Sofinnova Partners

sofinnovapartners.comSEP 22, 2026

SEP 22, 2026

News

Feature piece on Sofinnova Partners' decade-long backing of HighLife ahead of its recent $90M+ raise.

Before the breakthrough: Sofinnova's decade-long bet on HighLife

HighLife Sofinnova Partners

sofinnovapartners.comSEP 22, 2026

SEP 22, 2026

Investment

Portfolio company HighLife raised over $90 million to start its US pivotal study and accelerate commercial expansion in Europe.

HighLife

HighLife Sofinnova Partners

sofinnovapartners.comSEP 22, 2026

SEP 22, 2026

3 milestones· SEP 2026Show all

Milestone

Portfolio company Bionyra Pharma dosed first healthy volunteers in a Phase 1 study of BYN-001, a long-acting IL-25 antibody for atopic dermatitis.

Bionyra

Bionyra Sofinnova Partners

sofinnovapartners.comSEP 10, 2026

SEP 10, 2026

Milestone

Portfolio company Actithera strengthened its leadership team and Board as it advances toward clinical development.

Actithera

Actithera Sofinnova Partners

sofinnovapartners.comSEP 10, 2026

SEP 10, 2026

Milestone

Portfolio company NodThera renamed itself Rezera and announced a Phase 3 development program for ruvonoflast.

Rezera (formerly NodThera)

Rezera (formerly NodThera)Sofinnova Partners

sofinnovapartners.comSEP 9, 2026

SEP 9, 2026

New Fund

Closed Sofinnova Capital XI at €650 million (~$750M), exceeding target, to back early-stage biopharma and medtech start-ups.

Sofinnova Capital XI

Sofinnova Partners

biopharmadive.comNOV 2025

NOV 2025